Peringatan Keamanan

Acute oral toxicity (LD50): >5000 mg/kg Rat. Information on overdosage in humans is not available.

Spectinomycin

DB00919

small molecule approved investigational vet_approved

Deskripsi

An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.

Struktur Molekul 2D

Berat 332.3496
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 1 to 3 hours in patients with normal renal function and 10 to 30 hours in patients with impaired renal function with a creatinine clearance < 20 mL per minute.
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Rapidly and almost completely absorbed after intramuscular injection.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

55 Data
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Spectinomycin.
BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Spectinomycin.
Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Spectinomycin.
Dicoumarol The risk or severity of bleeding can be increased when Spectinomycin is combined with Dicoumarol.
Phenindione The risk or severity of bleeding can be increased when Spectinomycin is combined with Phenindione.
Warfarin The risk or severity of bleeding can be increased when Spectinomycin is combined with Warfarin.
Phenprocoumon The risk or severity of bleeding can be increased when Spectinomycin is combined with Phenprocoumon.
Acenocoumarol The risk or severity of bleeding can be increased when Spectinomycin is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of bleeding can be increased when Spectinomycin is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of bleeding can be increased when Spectinomycin is combined with Coumarin.
(R)-warfarin The risk or severity of bleeding can be increased when Spectinomycin is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of bleeding can be increased when Spectinomycin is combined with Ethyl biscoumacetate.
Fluindione The risk or severity of bleeding can be increased when Spectinomycin is combined with Fluindione.
Clorindione The risk or severity of bleeding can be increased when Spectinomycin is combined with Clorindione.
Diphenadione The risk or severity of bleeding can be increased when Spectinomycin is combined with Diphenadione.
Tioclomarol The risk or severity of bleeding can be increased when Spectinomycin is combined with Tioclomarol.
(S)-Warfarin The risk or severity of bleeding can be increased when Spectinomycin is combined with (S)-Warfarin.
Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Spectinomycin.
Vibrio cholerae CVD 103-HgR strain live antigen The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Spectinomycin.
Estetrol The therapeutic efficacy of Estetrol can be decreased when used in combination with Spectinomycin.
Lidocaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Lidocaine.
Ropivacaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Ropivacaine.
Bupivacaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Bupivacaine.
Cinchocaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Cinchocaine.
Dyclonine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Dyclonine.
Procaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Procaine.
Prilocaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Prilocaine.
Proparacaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Proparacaine.
Meloxicam The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Meloxicam.
Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Oxybuprocaine.
Cocaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Cocaine.
Mepivacaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Mepivacaine.
Levobupivacaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Levobupivacaine.
Diphenhydramine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Diphenhydramine.
Benzocaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Benzocaine.
Chloroprocaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Chloroprocaine.
Phenol The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Phenol.
Tetrodotoxin The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Tetrodotoxin.
Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Benzyl alcohol.
Capsaicin The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Capsaicin.
Etidocaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Etidocaine.
Articaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Articaine.
Tetracaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Tetracaine.
Propoxycaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Propoxycaine.
Pramocaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Pramocaine.
Butamben The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Butamben.
Butacaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Butacaine.
Oxetacaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Oxetacaine.
Ethyl chloride The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Ethyl chloride.
Butanilicaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Butanilicaine.
Metabutethamine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Metabutethamine.
Quinisocaine The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Quinisocaine.
Cisatracurium Spectinomycin may increase the neuromuscular blocking activities of Cisatracurium.
Ambroxol The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Ambroxol.
Fecal microbiota The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Spectinomycin.

Target Protein

30S ribosomal protein S12 rpsL

Referensi & Sumber

Synthesis reference: David R. White, "Intermediate compounds in the preparation of spectinomycin." U.S. Patent US4344882, issued August, 1966.

Contoh Produk & Brand

Produk: 2 • International brands: 3
Produk
  • Trobicin
    Solution • 400 mg/1mL • Intramuscular • US • Approved
  • Trobicin Inj 400mg/ml
    Powder, for solution • 400 mg / mL • Intramuscular • Canada • Approved
International Brands
  • Actinospectacin
  • Spectam
  • Togamycin

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul